|
|
Theramide® |
|
Vaxjo ID |
42 |
|
Vaccine Adjuvant Name |
Theramide® |
|
Adjuvant VO ID |
VO_0001317
|
|
Description |
The drug compound Theramide is a potent macrophage activator and adjuvant (Vogel and Powell, 1995). |
|
Stage of Development |
Research |
|
Components |
N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP) (Vogel and Powell, 1995). |
|
Function |
Theramide induces IL-6, IL-12, TNF, IFN-γ ,and relatively lessor quantities of IL-10. The compound preferentially induces cellular immunity. When reconstituted, it spontaneously forms liposomes in which lipopeptides may be incorporated. The compound augments both cellular and humoral immunity and is active in murine models of CMV. (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
